Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
PIOGLITAZONE HYDROCHLORIDE
Rowex Ltd
PIOGLITAZONE HYDROCHLORIDE
45 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
PACKAGE LEAFLET: INFORMATION FOR THE USER PIOGLITAZONE ROWEX 15 MG TABLETS PIOGLITAZONE ROWEX 30 MG TABLETS PIOGLITAZONE ROWEX 45 MG TABLETS Pioglitazone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or your pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Pioglitazone Rowex is and what it is used for 2. What you need to know before you take Pioglitazone Rowex 3. How to take Pioglitazone Rowex 4. Possible side effects 5. How to store Pioglitazone Rowex 6. Contents of the pack and other information 1. WHAT PIOGLITAZONE ROWEX IS AND WHAT IT IS USED FOR Pioglitazone Rowex contains pioglitazone. It is an anti-diabetic medicine used to treat type 2 (non- insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work adequately. This is the diabetes that usually develops in adulthood. Pioglitazone Rowex helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. Your doctor will check whether Pioglitazone Rowex is working 3 to 6 months after you start taking it. Pioglitazone Rowex may be used on their own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pioglitazone Rowex 45 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 45 mg pioglitazone (as pioglitazone hydrochloride). Excipient(s) with known effect: Lactose monohydrate 231 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet White, round tablet, with imprint “PGT 45” on one side and with three-part score line on the other side. The tablet can be divided into three equal parts. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as MONOTHERAPY - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4). After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily. The dose may be increased in increments up to 45 mg once daily. In combination with insulin, the current insulin dose can be continued upon i read_full_document